Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

If preservative-free dexamethasone 0.1 mg/kg (max dose 4 mg) is added to ropivacaine 0.5% 2 mg/kg (max dose 100 mg), then post-PACU opioid consumption will be reduced by 33%.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nationwide Children's Hospital
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Ropivacaine

Criteria

Inclusion Criteria:

• Children older than 10, and younger than 19 years of age undergoing unilateral arthroscopic surgery of the knee

• American Society of Anesthesiologists (ASA) Status I or II

• Patient's parent/guardian willing and able to give consent

• Patient willing to give assent

Exclusion Criteria:

• Arthroscopic anterior cruciate ligament repair

• Systemic steroid use within the last 3 months

• Diabetes mellitus

• Females testing positive for pregnancy

• BMI > 98th percentile

• Positive pregnancy test

• Coagulopathy

• Renal or hepatic disease

• Pre-existing motor or sensory deficits in the lower extremities

• Predisposition for falls based on pre-existing sensory or motor deficits of the legs or inability to perform crutch training.

• Non-English speaking

• Systemic fungal infection

• Immunosuppressed patients